Dr. Uprety is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4100 John R St
Detroit, MI 48201Phone+1 313-576-8722
Summary
- Dr. Dipesh Uprety is an oncologist based in Detroit, MI, specializing in thoracic cancer. He completed his residency in Internal Medicine at Abington Memorial Hospital in 2016 and a fellowship in Hematology and Medical Oncology at Gundersen Lutheran Medical Foundation in 2019. He graduated from B.P. Koirala Institute of Health Sciences in 2009. Dr. Uprety has several publications related to lung cancer and disparities in cancer outcomes, with his work featured in journals like The Lancet Oncology and the Journal of the National Cancer Institute. He is actively involved in multiple clinical trials focusing on non-small cell lung cancer and advanced solid tumors.
Education & Training
Gundersen Lutheran Medical FoundationFellowship, Hematology and Medical Oncology, 2019
Abington Memorial HospitalResidency, Internal Medicine, 2013 - 2016
B.P. Koirala Institute of Health SciencesClass of 2009
Certifications & Licensure
MI State Medical License 2020 - 2026
MN State Medical License 2019 - 2020
WI State Medical License 2016 - 2019
PA State Medical License 2013 - 2016- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C Start of enrollment: 2023 Dec 21
- A Study of DF6002 Alone and in Combination With Nivolumab Start of enrollment: 2020 Jul 13
- A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements Start of enrollment: 2017 Mar 07
- Join now to see all
Publications & Presentations
PubMed
- Adjuvant Immunotherapy Should Be Used in Patients With Non-Small Cell Carcinoma With a Pathologic Complete Response to Neoadjuvant Immunotherapy.Dipesh Uprety, Anja C Roden, Solange Peters
Journal of Thoracic Oncology. 2025-01-01 - 2 citationsSurvival trends among patients with metastatic non-small cell lung cancer before and after the approval of immunotherapy in the United States: A Surveillance, Epidemio...Yating Wang, Kyle Kondrat, Janak Adhikari, Quynh Nguyen, Qian Yu
Cancer. 2025-01-01 - Molecular and immune landscape of tumours in geriatric patients with non-small cell lung cancer, melanoma and renal cell carcinoma.Khalil Choucair, Andrew Elliott, Matthew James Oberley, Phillip Walker, April K Salama
BMJ Oncology. 2025-01-01
Press Mentions
Deaths from Advanced Lung Cancer Have Dropped Significantly Since Immunotherapy Became Standard-of-CareAugust 12th, 2024- Advanced Lung Cancer Deaths Drop with ImmunotherapyAugust 7th, 2024
- The Largest Population-Based Study to Date Supports the Survival Benefits of Immunotherapy for People with Metastatic Non-Small Cell Lung CancerJuly 29th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
